J Korean Soc Coloproctol.  2009 Jun;25(3):178-185. 10.3393/jksc.2009.25.3.178.

Feasibility of York-Mason Operation for Selective Advanced Rectal Cancer

• Jeong WK
• Baek SK
• Bae OS

• KMID: 1966629
• DOI: http://doi.org/10.3393/jksc.2009.25.3.178

Abstract

PURPOSE: The York-Mason operation has been used as local therapy for benign rectal tumors not easily excised with a conventional transanal excision and for T1 rectal cancers having a low risk of lymph-node metastasis. This study evaluated whether a York-Mason operation could be an alternative therapy for selected patients with T2 or T3 rectal cancers.
METHODS
From February 2004 to March 2008, 11 patients with T2 or T3 rectal cancer, who refused rectal excision due to fear of abdominal surgery itself and perioperative side effects or unwillingness to have a permanent stoma, underwent a York-Mason operation. The data on the patients were analyzed retrospectively.
RESULTS
The distance from the anal verge to the tumor was 5 cm (median, 2-8 cm), and the tumor size was 3 cm (median, 1.5-4 cm). Histological examination revealed a pathological tumor (pT) stage 2 in eight patients, stage pT3 in one patient, and stage pTx in two patients. The distance from the resection margin to the tumor was 0.3 cm (median, 0.1-0.5 cm). Six patients (55%) had incomplete tumor excision. Radiotherapy was performed in one patient preoperatively and in eight postoperatively. Postoperative morbidity occurred in four patients (36%). During a median of 38.2 months, two patients (18%) developed local recurrence and liver metastasis. Postoperative mortality, which was not related to the procedure, occurred in one patient (9%).
CONCLUSION
The York-Mason operation could be considered as an alternative therapy for selected T2 or T3 rectal cancer patients who refuse rectal excision.

Keyword

York-Mason operation; Transsphincteric excision; Local excision; Rectal cancer

MeSH Terms

Humans
Liver
Neoplasm Metastasis
Rectal Neoplasms
Recurrence
Retrospective Studies